Healthcare provider profile · identity verified

Nicholas Shih, D.O.

Family Practice · PARMA, OH · NPI 1316351083

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	374	138
Amlodipine Besylate	Amlodipine Besylate	266	95
Lisinopril	Lisinopril	132	58
Levothyroxine Sodium	Levothyroxine Sodium	120	41
Losartan Potassium	Losartan Potassium	106	39
Albuterol Sulfate Hfa	Albuterol Sulfate	100	44
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	90	39
Tamsulosin Hcl	Tamsulosin Hcl	90	33
Hydrochlorothiazide	Hydrochlorothiazide	86	33
Gabapentin	Gabapentin	84	37
Metformin Hcl	Metformin Hcl	79	30
Fluticasone Propionate	Fluticasone Propionate	78	26
Metoprolol Tartrate	Metoprolol Tartrate	73	27
Famotidine	Famotidine	68	25
Atenolol	Atenolol	59	29
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	53	22
Simvastatin	Simvastatin	49	21
Tramadol Hcl	Tramadol Hcl	49	12
Furosemide	Furosemide	45	19
Allopurinol	Allopurinol	44	16
Metformin Hcl Er	Metformin Hcl	43	18
Ciclopirox	Ciclopirox	41	17
Glipizide	Glipizide	41	19
Ibuprofen	Ibuprofen	41	24
Metoprolol Succinate	Metoprolol Succinate	39	14
Pantoprazole Sodium	Pantoprazole Sodium	39	15
Hydralazine Hcl	Hydralazine Hcl	38	14
Trazodone Hcl	Trazodone Hcl	36	14
Wixela Inhub	Fluticasone Propion/Salmeterol	35	suppressed
Alvesco	Ciclesonide	33	20
Potassium Chloride	Potassium Chloride	33	11
Carvedilol	Carvedilol	31	11
Lorazepam	Lorazepam	31	suppressed
Morphine Sulfate Er	Morphine Sulfate	31	suppressed
Jardiance	Empagliflozin	27	13
Oxycodone Hcl	Oxycodone Hcl	26	suppressed
Terazosin Hcl	Terazosin Hcl	26	12
Acetaminophen-Codeine	Acetaminophen With Codeine	25	suppressed
Omeprazole	Omeprazole	25	13
Colchicine	Colchicine	24	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	24	18
Lovastatin	Lovastatin	24	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	24	15
Hydrocortisone	Hydrocortisone	23	11
Alendronate Sodium	Alendronate Sodium	22	11
Naproxen	Naproxen	22	12
Pravastatin Sodium	Pravastatin Sodium	21	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	20	20
Finasteride	Finasteride	20	suppressed
Duloxetine Hcl	Duloxetine Hcl	19	suppressed
Pregabalin	Pregabalin	19	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	18	suppressed
Clobetasol Propionate	Clobetasol Propionate	18	suppressed
Clopidogrel	Clopidogrel Bisulfate	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	16
Sertraline Hcl	Sertraline Hcl	18	suppressed
Amoxicillin	Amoxicillin	17	suppressed
Bupropion Xl	Bupropion Hcl	17	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	17	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Montelukast Sodium	Montelukast Sodium	15	suppressed
Prednisone	Prednisone	15	11
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	15
Nitroglycerin	Nitroglycerin	14	suppressed
Fluocinonide	Fluocinonide	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Temazepam	Temazepam	13	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	12	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	11	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	11	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error